NEW ORLEANS--10 Nov--PRNewswire-AsiaNet/InfoQuest
New data from the JUPITER study demonstrated that CRESTOR(R) (rosuvastatin calcium) 20 mg significantly reduced major cardiovascular (CV) events (defined in this study as the combined risk of myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or death from CV causes) by a dramatic 44% compared to placebo (p